NeuroVive Pharmaceutical AB Stock Swiss Exchange
Equities
NVP
SE0002575340
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 235M 22.29M 30.69M |
---|---|---|---|---|---|
Net income 2024 * | -128M -12.15M -16.73M | Net income 2025 * | -146M -13.86M -19.08M | EV / Sales 2024 * | - |
Net cash position 2024 * | 22M 2.09M 2.88M | Net cash position 2025 * | 82M 7.78M 10.72M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.74
x | P/E ratio 2025 * |
-1.45
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.06% |
Latest transcript on NeuroVive Pharmaceutical AB
Managers | Title | Age | Since |
---|---|---|---|
Ellen Donnelly
CEO | Chief Executive Officer | 50 | 21-02-02 |
Eskil Elmér
FOU | Founder | 54 | 00-01-31 |
Director of Finance/CFO | 57 | 13-11-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 70 | 16-04-27 | |
David Bejker
BRD | Director/Board Member | 49 | 17-04-26 |
Eskil Elmér
FOU | Founder | 54 | 00-01-31 |
1st Jan change | Capi. | |
---|---|---|
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |